Questions With Complete Solutions Grade
A+
1. Many tumors have begun to metastasize at the time of
detection. What percentage? - ANSWER It is estimated that
60% of patients with solid tumors have microscopic or
macroscopic metastasis at diagnosis
2. How does Heterogeneity of tumor affect metastasis? -
ANSWER Each cell within tumor mass is not equal in
metabolic needs, resistance to treatment, etc.
3. What signaling protein allows for endothelial cells to
migrate to growing tumors?? - ANSWER Tumor necrosis
factor-alpha stimulates migration of endothelial cells
4. Which pro-angiogenic growth factor is over expressed in a
wide range of solid tumors? - ANSWER Vascular
endothelial growth factor (VEGF)
,5. Overexpression of what protein in cancer cells breaks down
EC matrix and basement membranes and is associated with
decreased survival - ANSWER Matrix metalloproteinases
(MMP) are proteolytic enzymes that degrade EC matrix
and basement membrane
6. Recent data supports hypothesis that cancer cells interact
with____________ to stimulate and release ______. -
ANSWER local stromal cells
MMP
7. How is immune function related to decreased cancer
survival? - ANSWER Deficient immune function can
promote escape from immune destruction of tumor cells
8. What are 2 ways metastatic cancer cells use platelets to
their benefit? - ANSWER - Malignant cells secrete
substances that signal platelet aggregation which
maximizes their ability to arrest in blood vessel.
- Tumor-platelet aggregate may be protected from
immune cell penetration
9. Why is normal platelet function is required for optimal
metastasis? - ANSWER Unless tumor cell can enter
, capillary bed, it will most likely not survive the hostile
environment of the circulation
10. What are 4 common sites of metastasis? - ANSWER
Bone
Lung
Liver
CNS
11. What are the 5 steps in metastatic process - ANSWER
Detachment from primary tumor
Invasion of surrounding tissue, entry into lymphatic vessel
or blood vessel
Survival in transport
Arrest in distant organ capillary bed
Establishment of secondary tumor